Using platelet markers to improve heart attack treatment
Validation of Platelet Expression of FcɣRIIa as a Precision Tool
This study is looking at a special marker in your blood that could help doctors personalize treatment for people at risk of heart attacks, aiming to find the best way to prevent future heart issues while keeping side effects low.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Prolocor INC. NIH-funded |
| Lab location | 1 site (Shelburne, United States) |
| Project ID | NIH-10897855 on NIH RePORTER |
What this research studies
This research investigates the role of a specific platelet marker, FcγRIIa, in personalizing treatment for patients at risk of heart attacks. By identifying patients with high levels of this marker, the study aims to tailor antiplatelet therapy to reduce the risk of recurrent ischemic events while minimizing bleeding complications. The approach involves analyzing platelet function and its variability to better predict patient outcomes. This could lead to more effective and individualized cardiovascular care.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with a history of coronary events or those at high risk for ischemic complications.
Not a fit: Patients who do not have cardiovascular risk factors or a history of coronary events may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatments for patients at risk of heart attacks, potentially reducing the incidence of recurrent events.
How similar studies have performed: Previous research has shown promise in using platelet function tests for risk stratification, but this specific approach using FcγRIIa as a biomarker is novel.
Where this research is happening
Shelburne, United States
- Prolocor INC. — Shelburne, United States (Active)
Researchers
- Principal investigator: Ohrnberger, Jeanne — Prolocor INC.
- Study coordinator: Ohrnberger, Jeanne
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.